The "Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)" trial, conducted at Yeolyan Hematology and Oncology Center, has successfully enrolled 5 lymphoma patients thus far. Among the participants, 2 patients have demonstrated a positive treatment response, as evidenced by control CT scans. The remaining patients are awaiting further control studies to assess treatment efficacy.
This ongoing trial holds promise for evaluating the safety and effectiveness of Balstilimab in addressing relapsed/refractory lymphomas.
The Principle Investigator of the trial is Dr. Astghik Voskanyan.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048